Bronte Capital Management Pty Ltd.
13F Reported Value
ⓘ$1.0B
incl. option notional
Equity Holdings
ⓘ$940.9M
Option Notional
ⓘ$68.9M
$0 puts / $68.9M calls
Holdings
54
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
Bronte Capital Management Pty Ltd. disclosed 54 positions worth $1.0B in its Form 13F-HR for Q1 2026 — $940.9M in common stock plus $68.9M of put/call option positions (reported at underlying notional value, not premium at risk), led by $REGN (REGENERON PHARMACEUTICALS, INC.) at 14.2% of the equity portfolio, followed by $GOOG and $IBKR. During the quarter the fund opened 10 new positions and exited 1 — including a new stake in $DIS and a full exit from $FICO. The portfolio is most concentrated in Financials (24.2% of disclosed assets). All figures are sourced directly from Bronte Capital Management Pty Ltd.’s Form 13F-HR filing with the SEC under CIK 1471085.
AI Fund Analysis
Diversifying
Sector Allocation
AUM History
Top Equity Holdings by Value
Option Positions
13F rules report options at the value of the underlying shares (notional) — not the premium paid or capital at risk. Shown separately from the equity sleeve above.
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- 75.1#138
Quality
$133.5M172,787 sh - 80.2#45
Quality
$109.7M381,490 sh - 75.5#124
Quality
$86.0M1,281,731 sh - 64.5
Quality
$74.3M155,063 sh VISA INC-CLASS A SHARES
—Quality
$72.3M239,370 sh- 74.6
Quality
$59.5M285,739 sh - 80.5
Quality
$56.4M341,098 sh - 75.1
Quality
$53.0M68,600 sh - 48.4
Quality
$42.1M502,790 sh - 71.0
Quality
$34.2M187,369 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 REGENERON PHARMACEUTICALS, INC.$REGN | 75.1#138 | $133.5M | 172,787 |
 Alphabet Inc.$GOOG | 80.2#45 | $109.7M | 381,490 |
 Interactive Brokers Group, Inc.$IBKR | 75.5#124 | $86.0M | 1,281,731 |
 BERKSHIRE HATHAWAY INC$BRK.B | 64.5 | $74.3M | 155,063 |
| VISA INC-CLASS A SHARES | — | $72.3M | 239,370 |
 AMAZON COM INC$AMZN | 74.6 | $59.5M | 285,739 |
 Philip Morris International Inc.$PM | 80.5 | $56.4M | 341,098 |
| REGENERON PHARMACEUTICALS, INC.$REGNCALL | 75.1 | $53.0M | 68,600 |
 Corteva, Inc.$CTVA | 48.4 | $42.1M | 502,790 |
 CAPITAL ONE FINANCIAL CORP$COF | 71.0 | $34.2M | 187,369 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Bronte Capital Management Pty Ltd.'s 54 positions.
Showing top 10 of 54 holdings.
Sector Allocation
Financials
$227.7M
Healthcare
$172.4M
Consumer Staples
$152.3M
Technology
$147.1M
Other
$118.1M
Consumer Discretionary
$79.0M
Materials
$24.5M
Communication Services
$17.9M
Full Holdings — Bronte Capital Management Pty Ltd. (Q1 2026)
All 54 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $REGN | REGENERON PHARMACEUTICALS, INC. | $133.5M | 14.2% | -2% | 75.1 |
| 2 | $GOOG | Alphabet Inc. | $109.7M | 11.7% | -8% | 80.2 |
| 3 | $IBKR | Interactive Brokers Group, Inc. | $86.0M | 9.1% | -14% | 75.5 |
| 4 | $BRK.B | BERKSHIRE HATHAWAY INC | $74.3M | 7.9% | -4% | 64.5 |
| 5 | — | VISA INC-CLASS A SHARES | $72.3M | 7.7% | +2% | — |
| 6 | $AMZN | AMAZON COM INC | $59.5M | 6.3% | +3% | 74.6 |
| 7 | $PM | Philip Morris International Inc. | $56.4M | 6.0% | -14% | 80.5 |
| 8 | $REGNCALL | REGENERON PHARMACEUTICALS, INC. | $53.0M | — | +16% | 75.1 |
| 9 | $CTVA | Corteva, Inc. | $42.1M | 4.5% | -12% | 48.4 |
| 10 | $COF | CAPITAL ONE FINANCIAL CORP | $34.2M | 3.6% | +7% | 71 |
| 11 |  $FCNCA | FIRST CITIZENS BANCSHARES INC /DE/ | $31.1M | 3.3% | -3% | 54.8 |
| 12 | — | VANECK ETF TRUST | $19.1M | 2.0% | -4% | — |
| 13 |  $DIS | Walt Disney Co | $17.9M | 1.9% | NEW | 68.9 |
| 14 |  $TBBB | BBB FOODS INC | $17.2M | 1.8% | +24% | — |
| 15 |  $NKTRCALL | NEKTAR THERAPEUTICS | $14.6M | — | NEW | 10.2 |
| 16 | $NKTR | NEKTAR THERAPEUTICS | $14.3M | 1.5% | NEW | 10.2 |
| 17 |  $HLF | HERBALIFE LTD. | $13.8M | 1.5% | -16% | — |
| 18 |  $GHC | Graham Holdings Co | $13.5M | 1.4% | -4% | 62 |
| 19 |  $BF-A | BROWN FORMAN CORP | $13.1M | 1.4% | NEW | 65.1 |
| 20 |  $ALNY | ALNYLAM PHARMACEUTICALS, INC. | $12.3M | 1.3% | -4% | 60.9 |
| 21 |  $SHC | Sotera Health Co | $12.1M | 1.3% | -4% | 59.7 |
| 22 | — | ISHARES TR | $11.8M | 1.3% | -48% | — |
| 23 | — | ISHARES TR | $11.7M | 1.2% | -4% | — |
| 24 |  $SQM | CHEMICAL & MINING CO OF CHILE INC | $9.9M | 1.1% | -25% | — |
| 25 |  $AUR | Aurora Innovation, Inc. | $9.6M | 1.0% | NEW | 9.8 |
| 26 |  $NEM | NEWMONT Corp /DE/ | $8.2M | 0.9% | -3% | 88.3 |
| 27 |  $PINS | PINTEREST, INC. | $7.9M | 0.8% | -16% | 62 |
| 28 |  $GLBE | Global-E Online Ltd. | $6.6M | 0.7% | NEW | — |
| 29 |  $B | BARRICK MINING CORP | $6.5M | 0.7% | -4% | — |
| 30 |  $RAMP | LiveRamp Holdings, Inc. | $5.9M | 0.6% | -4% | 66.7 |
| 31 |  $PCTY | Paylocity Holding Corp | $4.0M | 0.4% | NEW | 72.7 |
| 32 |  $TPB | Turning Point Brands, Inc. | $3.7M | 0.4% | +76% | 57.7 |
| 33 |  $MDLZ | Mondelez International, Inc. | $3.2M | 0.3% | -13% | 53.9 |
| 34 | — | VANECK ETF TRUST | $3.2M | 0.3% | -4% | — |
| 35 |  $SBH | Sally Beauty Holdings, Inc. | $3.1M | 0.3% | -70% | 53.6 |
| 36 |  $BBWI | Bath & Body Works, Inc. | $2.9M | 0.3% | -39% | 59.8 |
| 37 | $BF-A | BROWN FORMAN CORP | $2.7M | 0.3% | NEW | 65.1 |
| 38 |  $JRVR | James River Group Holdings, Inc. | $2.1M | 0.2% | +174% | 34.3 |
| 39 |  $RSKD | RISKIFIED LTD. | $1.9M | 0.2% | -5% | — |
| 40 |  $NICE | NICE Ltd. | $1.9M | 0.2% | -16% | — |
| 41 | — | ISHARES TR | $1.4M | — | NEW | — |
| 42 |  $OLED | UNIVERSAL DISPLAY CORP \PA\ | $1.0M | 0.1% | -5% | 64.7 |
| 43 |  $VRSK | Verisk Analytics, Inc. | $550,655 | 0.1% | NEW | 77.3 |
| 44 |  $ENVX | Enovix Corp | $59,829 | 0.0% | +0% | 25.2 |
| 45 |  $ALEC | Alector, Inc. | $41,456 | 0.0% | +0% | 8.9 |
| 46 |  $CHRS | Coherus Oncology, Inc. | $32,587 | 0.0% | +0% | 42.9 |
| 47 |  $CRBU | Caribou Biosciences, Inc. | $29,691 | 0.0% | +0% | 6.1 |
| 48 |  $FATE | FATE THERAPEUTICS INC | $27,424 | 0.0% | +0% | 6.7 |
| 49 |  $CCCC | C4 Therapeutics, Inc. | $26,387 | 0.0% | +0% | 6.5 |
| 50 |  $PLRX | PLIANT THERAPEUTICS, INC. | $23,452 | 0.0% | +0% | — |
| 51 |  $IVVD | Invivyd, Inc. | $14,316 | 0.0% | +0% | 25.7 |
| 52 |  $MIST | Milestone Pharmaceuticals Inc. | $12,393 | 0.0% | +0% | — |
| 53 |  $RANI | Rani Therapeutics Holdings, Inc. | $10,925 | 0.0% | +0% | — |
| 54 |  $GUTS | FRACTYL HEALTH, INC. | $7,739 | 0.0% | +0% | — |
New Positions (10)
$DIS Walt Disney Co$17.9M$NKTRCALL NEKTAR THERAPEUTICS$14.6M$NKTR NEKTAR THERAPEUTICS$14.3M$BF-A BROWN FORMAN CORP$13.1M$AUR Aurora Innovation, Inc.$9.6M$GLBE Global-E Online Ltd.$6.6M$PCTY Paylocity Holding Corp$4.0M$BF-A BROWN FORMAN CORP$2.7M$VRSK Verisk Analytics, Inc.$550,655Exited Positions (1)
$FICO FAIR ISAAC CORPBrowse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Bronte Capital Management Pty Ltd. including:
Track Bronte Capital Management Pty Ltd.'s Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Bronte Capital Management Pty Ltd. and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Bronte Capital Management Pty Ltd.
13F Pro is an AI hedge fund tracker and stock research platform. For Bronte Capital Management Pty Ltd. (SEC CIK: 1471085), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Bronte Capital Management Pty Ltd.'s portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.